Latest Breaking News On - மைல்கல் கட்டணம் - Page 6 : comparemela.com

TeneoBio, Inc Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase I study (https://clinicaltrials.gov/ct2/show/NCT04540796), which is sponsored by Janssen Research & Development, LLC (Janssen). The Phase I dose escalation study will evaluate patients with B-cell lymphoid malignancies, including non-Hodgkin s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Participants will receive JNJ-75348780 by intravenous (IV) or subcutaneous (SC) administra

Omid vafaTeneobio incJanssen research developmentTeneobio announces achievementMilestone paymentJanssen advances phasei studyJanssen researchHuman heavy chain antibodiesInvestegate announcementsInvestegate company announcementsGlobe newswireGlobenewswire andஓமித் வஃபாஜான்சன் ஆராய்ச்சி வளர்ச்சிமைல்கல் கட்டணம்ஜான்சன் ஆராய்ச்சி